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Abstract
Aims We aim to agree on a set of proposals to improve the current management of heart failure (HF) within the Spanish
National Health System (SNHS) and apply the social return on investment (SROI) method to measure the social impact that
these proposals would generate.
Methods and results A multidisciplinary working team of 16 experts was set up, with representation from the main stake-
holders regarding HF: medical specialists (cardiologists, internal medicine physicians, general practitioners, and geriatric phy-
sicians), nursing professionals, health management professionals, patients, and informal caregivers. This team established a set
of proposals to improve the management of HF according to the main areas of HF care: emergency and hospitalization, pri-
mary care, cardiology, and internal medicine. A forecast-type SROI method, with a 1-year time frame, was applied to measure
the social impact resulting from the implementation of these proposals. The required investment and social return were esti-
mated and summarized into a ratio indicating how much social return could be generated for each euro invested. Intangible
returns were included and quantified through financial proxies. The approach to improve the management of HF consisted of
28 proposals, including the implementation of a case management nurse network, standardization of operational protocols,
psychological support, availability of echocardiography machines at emergency departments, stationary units and primary
care, early specialist visits after hospital discharge, and cardiac rehabilitation units, among others. These proposals would ben-
efit not only patients and their informal caregivers but also the SNHS. Regarding patients, proposals would increase their au-
tonomy in everyday activities, decrease anxiety, increase psychological and physical well-being, improve pharmacological
adherence and self-care, enhance understanding of the disease, delay disease progression, expedite medical assessment,
and prevent the decrease in work productivity associated with HF management. Regarding informal caregivers, proposals
would increase their quality of life; improve their social, economic, and emotional well-being; and reduce their care burden.
The SNHS would benefit from shorter stays of HF patients at intensive care units and reduction of hospitalizations and admis-
sions to emergency departments. The investment needed to implement these proposals would amount to €548m and yield a
social return of €1932m, that is, €3.52 for each euro invested.
Conclusions The current management of HF could be improved by a set of proposals that resulted in an overall positive so-
cial return, varying between areas of analysis. This may guide the allocation of healthcare resources and improve the quality of
life of patients with HF.
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Introduction
Heart failure (HF) is a clinical syndrome caused by structural
and/or functional alterations of myocardium, which result in
reduced cardiac output and/or raised intracardiac pressures
at rest or during physical exertion.1 While characterized by
impaired systolic and/or diastolic ventricular function, its clin-
ical manifestations are related to haemodynamic effects on
other organs.2 In Spain, HF prevalence is 4.7% for population
≥ 18 years old and 6.8% for population > 44 years old.3 This
incidence has achieved a rate of 3.9/1000 inhabitants.4 In
2015, cardiovascular diseases were considered the second
cause of death in Spain, with 22.3% of these deaths caused
by HF, with an age-adjusted mortality rate of 16.8/100 000
inhabitants.5
This syndrome is associated with an unfavourable progno-
sis, given that 50% to 65% of patients with HF die within 5
years of diagnosis.6,7 Furthermore, the presence of co-
morbidities, such as arterial hypertension, diabetes mellitus,
and hypercholesterolaemia, are considered detrimental fac-
tors for this syndrome.8 In addition, patients with HF usually
require assistance in their everyday activities, as the disease
significantly affects their work environment, as well as emo-
tional, sexual, and social status. Similarly, informal caregivers
also suffer from a negative impact primarily on emotional,
physical, and economic levels. Thus, HF patients and their
families experience a significant decline of physical and psy-
chological health.9–13
Consequently, the management of HF should be addressed
in a holistic manner. Therefore, an improvement of the cur-
rent approach is necessary to provide an answer to the un-
met needs that benefit the Spanish National Health System
(SNHS), patients with HF, and their informal caregivers. Cor-
respondingly, a comprehensive evaluation of improvements
is deemed necessary.
Accordingly, the social return on investment (SROI)
method, developed in 1996 by the Roberts Enterprise Devel-
opment Fund, may account for the social value of the holistic
management of HF. The main motivation for developing the
SROI framework was to measure returns that do not have a
market value but possess an intrinsic value (e.g. emotional
well-being of patients or doctor–patient relationship).14 The
application of this method helped to improve the assessment
of social value, as every intervention could create or destroy
social and environmental values.15
In subsequent revisions of the original SROI method, new
principles and processes normally used in evaluations of eco-
nomic and financial return on investment were added to cre-
ate a framework capable of capturing the total economic,
social, and environmental impact of the interventions.16 This
method has recently been used in the SNHS in the areas of
dermatology, cardiology, and oncology,17–19 as well as for
the management of viral infections, such as human immuno-
deficiency virus, childhood bronchial asthma, spinal cord
injuries,20 arterial hypertension and obesity,21 and paediatric
cancer22 in other countries. However, the SROI method has
not been applied to the management of HF. Therefore, the
objective of this study was twofold: first, to agree on a set
of proposals that could potentially improve the current man-
agement of HF within the SNHS and, second, to apply the
SROI method to measure the social impact that these pro-
posals would generate, including the intangible aspects of
the disease.
Methods
The six stages of the SROI analysis were used to achieve the
goals of the present study: (i) to establish scope and identify
stakeholders; (ii) to map outcomes; (iii) to evidence and give
them a value; (iv) to establish the impact; (v) to calculate the
SROI; and (vi) to report to the stakeholders, use the results,
and embed the SROI process. The first four stages of the SROI
analysis were based on the collection of relevant data from
the following sources.
(a) Literature review
We reviewed scientific articles, official data, and, to a
lesser extent, grey literature. This helped design a survey to
collect relevant data from patients with HF and their informal
caregivers. Moreover, the evidence was gathered to obtain
necessary information for the SROI analysis.
(b) Surveys for patients with HF and their informal caregivers
A survey was administered from May to August 2016
among HF patients and their informal caregivers, of legal
age and living in Spain, to analyse the impact of HF on each
life domain. The patient survey, designed ad hoc for this
study, contained a sub-questionnaire addressed to the pa-
tients’ primary informal caregiver.
In addition, a five-level health-related quality of life (EQ-
5D©) questionnaire was delivered to patients and caregivers;
and a 12-item General Health Questionnaire, a screening tool
for minor psychiatric disorders, was administered to HF pa-
tients. In brief, the EQ-5D© evaluates mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression on
a scale ranging from ‘no problems’ to ‘extreme problems’.
Two data collection methods were used to obtain a larger
sample size: paper-based surveys and an online reproduction
of the paper-based format. Owing to the difficulty of
obtaining a random sample of HF population across the coun-
try, patients were mainly recruited through cardiovascular
disease associations grouped in the CardioAlianza association,
following the inclusion criteria designed by expert cardiolo-
gists and internal medicine physicians. HF patients ≥18 years
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old, living in Spain, and who had at least one of the following
symptoms in the past year, were included in the study popu-
lation: shortness of breath during or after physical exercise,
exertion, or while lying down; peripheral oedema and/or as-
cites; unexplained weight gain in the past week; feeling full
or stomach bloating; nocturia; or fatigue. Overall, the study
sample consisted of 558 patients with HF.
The exclusion criteria were underage subjects, patients liv-
ing abroad, those who did not have any of the symptoms re-
ferred to in the inclusion criteria, or those with any limitation
on responding to the questionnaire (no knowledge of Span-
ish, cognitive disability, etc.).
The calculated sample error (from HF prevalence in Spain23
and population data24) was 4.15% (level of confidence: 95%;
distribution p = q = 0.5). This survey did not require the ap-
proval of an ethics committee yet conforms with the princi-
ples outlined in the Declaration of Helsinki.
(c) Expert consultation
A multidisciplinary working team (MWT) consisting of 16
experts was set up, with representation from the main stake-
holders regarding HF: medical specialists (cardiologists, inter-
nal medicine physicians, general practitioners, and geriatric
physicians), nursing and health management professionals,
patients, and informal caregivers. Four of the 16 experts
formed the Project Advisory Committee to establish the cur-
rent approach to HF (starting point) and, together with the
rest of the experts, agreed on a set of proposals aimed to im-
prove the management of HF patients (first objective).
During an extensive meeting, the MWT was organized into
the three subgroups from the perspectives of medicine, nurs-
ing, and patients. Each group discussed the most relevant
proposals. Thereafter, these were shared with the rest of
the groups via a spokesperson and discussed and categorized
into four blocks that were previously established according to
the main areas of HF management: emergency and hospital-
ization (EH), primary care (PC), cardiology (C), and internal
medicine (IM).
Subsequently, the members of the MWT were asked to
rate the proposals according to their importance on a scale,
ranging from 0 (‘not important’) to 10 (‘maximum impor-
tance’). Finally, the technical team, on the basis of the basic
principle of economy of resource scarcity, decided to select
25% of the proposals with the highest average score in each
area. A new general (G) area was introduced to address HF
patients treated by different specialists.
Social return on investment analysis
To measure the social impact of selected proposals, a
forecast-type SROI method, with a 1-year time frame, was
applied. The analysis combined both qualitative and quantita-
tive methodologies, as indicated by the SROI guide.25 The in-
vestment was determined from the SNHS perspective, while
the impact was determined from a social perspective. The re-
lationship between investment and social return was pre-
sented by a ratio indicating how much social return could be
generated for each euro invested (Figure 1). The SROI frame-
work is based on seven principles: (i) involvement of stake-
holders, (ii) understanding of changes, (iii) evaluation of
significant factors, (iv) inclusion of material aspects, (v)
assessment of changes associated with the activity indepen-
dent of other factors, (vi) transparency, and (vii) verification
of the result.25 Initially, the costs associated with the activities
and resources required for implementation of each proposal
were identified, and the latter were multiplied by their unit
Figure 1 The association between investment, return, total impact, and SROI ratio. SROI, social return on investment.
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prices. These resources, be they medical or non-medical, or
material or human, they were quantified (in number and cost)
from literature sources, official data, public prices of health
services of the Spanish autonomous regions, and market
prices. Following the current convention on SROI methodol-
ogy, no financial value was given to the time spent on inter-
ventions by patients and caregivers (main beneficiaries).25
To calculate returns, the potential consequences of each
proposal from the clinical, welfare, economic, and social per-
spectives were identified. These returns, be they tangible or
intangible, or positive or negative, were obtained from the
MWT, literature review, official data, public prices of health
services of the Spanish autonomous regions, and market
prices. Finally, unit market prices and financial proxies (an ap-
proximate value when a return does not have a market price)
were used to evaluate the tangible and intangible returns, re-
spectively. The adjustment factors, including deadweight
(percentage of return that would have been obtained with-
out the proposal), attribution (percentage of the return
resulting from activities independent from the proposal), dis-
placement (percentage of the return that would have
displaced another return), and drop-off (percentage of return
deterioration over time) were deducted from the return (Fig-
ure 1). All calculations were based on the prevalence of HF in
Spain.4,23,24 In addition, the analyses were carried out with a
conservative perspective, so that the highest costs were cho-
sen among all the available ones, whereas for the returns, the
lowest monetary impact was taken into account. Missing data
points were added based on assumptions. Prices were up-
dated to euros from 2015 according to the corresponding
consumer price index.26
Finally, a sensitivity analysis was performed by comparing
three scenarios that considered the different ways of amor-
tizing the equipment acquisition investment27,28:
(a) the worst scenario, considering the total costs of the
equipment;
(b) an intermediate scenario, considering the minimum am-
ortization of the equipment; and
(c) the best scenario, considering the maximum amortiza-
tion of the equipment.
Results
The MWT agreed on a total of 28 proposals to improve the
current approach to HF management within the SNHS (Table
1). Proposal 17 has been used as an example of how out-
comes were mapped and evaluated, and impact established,
Table 1 The proposals to improve the current approach to heart failure in the Spanish National Health System
Areas of HF management Proposals
General 1. Optimization of the electronic medical record use
2. Enhancement of electronic prescription use
3. Implementation of a widespread hospital nurse case manager network
4. Realization of a widespread community nurse case manager network
5. Standardization of operational protocols between specialities attending the same patients
6. Application of a clinical pathway in each hospital
7. Psychological–emotional support of patients
8. Professional reorientation and insertion actions
Emergency and hospitalization 9. Monograph for palliative care patient identification
10. Informative dissemination of the advance directives document
11. Profile definition of a patient with acute HF and initial comprehensive assessment
12. Availability of echocardiography division at hospital emergency departments
13. Awareness campaign for health professionals on the importance of good communication with
patients at hospital discharge
14. Health education for patients and caregivers before hospital discharge
15. Telephone contact 48 hours after hospital discharge to home
Primary care 16. Quick access to the echocardiography in the primary care upon initial evaluation
17. Health education for patients with HF
18. Home visit within 7 days from hospital discharge
19. Early visit to the corresponding specialist within 2 weeks from hospital discharge
Cardiology 20.Implementation of cardiac rehabilitation units at reference hospitals
21. Nursing staff specialization at HF units
22. Approach for non-invasive mechanical ventilation in the emergency department, cardiology, and
acute care units
23. Early visit to the specialist indicated within 2 weeks from hospital discharge
24. Quick access to a clinical cardiologist
Internal medicine 25. Campaigns on the importance of good communication between healthcare professionals
and patients followed at the IM department
26. Social resource streamlining
27. Implementation of an optimal palliative care ratio
28. Early visit to the specialist indicated within 2 weeks from hospital discharge
DOI: 10.1002/ehf2.12535
ESC Heart Failure 2020; : 131–1387
M. Merino et al.134
according to the stages of SROI analysis. The details on each
proposal are presented in the Supporting Information.
Regarding the mapping of outcomes, Proposal 17 aimed to
improve physical and mental well-being of patients, decrease
hospital readmission, delay HF progression, increase labour
productivity, and reduce informal care hours (Table 3S). This
further implied an investment on three nursing appointments
per year for each patient (Table 2S).
To monetize the reduction in hospital readmission, Pro-
posal 17 used the number of readmissions due to HF, the per-
centage of reduction of readmissions due to pharmacological
adherence training, and cost of hospitalization. On the other
hand, to monetize the improvement of physical and mental
well-being, the average annual costs on leisure, entertain-
ment, and culture were used, which could be equivalent to
achieving well-being of patients in an alternative way.
In Proposal 17, to establish return related to delaying HF
progression includes an attribution correction of 50% (a con-
servative assumption), which means that half of the return
may be due to other causes, so the amount of return is re-
duced to half (Table S5).
Once the required total investment and the net social re-
turn were estimated, the SROI ratio was calculated (Figure
1). The investment for the first year would amount to
€548.1m, while the expected social return would amount to
€1931.7m. The main investment would be made in areas G
(€232.2m) and PC (€180.0m), followed by areas C, IM, and
EH (€86.3m, €39.6m, and €10.0m, respectively) (Table 2).
In addition, more than half of the total social return would
be obtained from area G (€1164.2m), followed by PC
(€515.5m) and to a lesser extent from areas C, EH, and IM
(€115.0m, €90.6m, and €46.4m, respectively) (Table 2). The
detailed evaluation of both the investment and the expected
social return for each proposal is presented in the tables of
the Supporting Information.
Therefore, the SROI ratio would yield a return of €3.52 for
each euro invested. The highest SROI ratios would be
achieved in the areas of EH and G (€9.05 and €5.01, respec-
tively). For the rest of areas of HF management, lower but
positive values for SROI ratios would be achieved (€2.86 in
PC, €1.33 in C, and €1.17 in IM). These ratios could poten-
tially be higher according to the results of the sensitivity anal-
ysis (Table 3).
The obtained results were reported to the Project Advisory
Committee for validation. Subsequently, they were disclosed
in 2017 at the congresses of the Spanish Society of Cardiol-
ogy,29 the Spanish Society of Internal Medicine,30 and the
Spanish Association of Health Economics,31 as well as via me-
dia and social networks.
Discussion
To our knowledge, this is the first study in Spain that has
quantified the social value generated by the implementation
of a set of proposals to improve the current HF approach in
the SNHS. Until now, the expenses related to the manage-
ment of HF have only been studied in terms of tangible
costs,11,13,32–34 without showing a complete overview of their
impact on patients’ lives, their informal caregivers, and the
society. There is no exact method to capture the social value,
but the traditional ones leave out of the analysis its total im-
pact. The SROI method, unlike other economic evaluation
methods, allows measuring a broader concept of value,35,36
as it quantifies the tangible and intangible social impact of
an intervention, compares it to the investment needed, and
gives an SROI ratio that expresses how much social return
could be obtained for each euro invested. Furthermore, it in-
cludes internal adjustment mechanisms that provide a con-
servative perspective during the processes of calculation
and analysis.
We have shown that the total investment for this approach
to HF would imply a social return of €3.52 for each euro
invested. Moreover, this amount could be greater because
the base case analysis corresponds to the most unfavourable
scenario of the sensitivity analysis, and it follows the princi-
ples on which the SROI method is based on, including a con-
servative character and trying not to overestimate the
potential of the social return and not to underestimate the
required expenses to achieve it. The involvement of stake-
holders related to HF and the consensus of proposals may en-
able a response to the existing gaps in the current
management of patients with HF.
Table 2 Investment and social return by areas of analysis
Areas of HF management Investment Social return
General €232.15 €1164.17
Emergency and hospitalization €10.02 €90.63
Primary care €180.01 €515.49
Cardiology €86.29 €115.00
Internal medicine €39.62 €46.40
Total €548.08 €1931.71














Primary care €2.86 €3.80 €3.96
Cardiology €1.33 €1.92 €1.99
Internal medicine €1.17 €1.17 €1.17
Total SROI €3.52 €4.09 €4.16
Note: The SROI ratio is the social return in euros for each euro
invested.
SROI, social return on investment.
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The implementation of this new approach in the SNHS
could substantially improve the quality of life of HF patients
and their informal caregivers, as well as optimize the use of
certain healthcare resources. This approach could prevent
the decrease in labour productivity and contribute to the re-
duction of informal caregiving while minimizing unnecessary
health expenses. The SROI ratio justifies addressing unmet
needs of HF patients through interventions that provide pos-
itive results for all stakeholders.
This study has several limitations. A different configuration
of MWT could have conducted a different set of proposals
from the ones presented in this paper. Therefore, the SROI
ratio would have been different. However, the proposals
are in line with the latest consensus of scientific societies.37
Furthermore, the New York Heart Association functional class
of the study patients with HF was not taken into account, an
important parameter that could have altered the results.
In conclusion, based on the SROI method, the implementa-
tion of proposals agreed upon to improve HF management
would result in a social return of €3.52 for each euro
invested. More specifically, the analysis of EH area of HF man-
agement yielded the highest SROI ratio, followed by G, PC, C,
and IM areas, respectively.
The present study provides valuable information that could
guide the allocation of healthcare resources with respect to
HF management and improve the quality of life of patients
with HF. Having proposals developed by stakeholders in-
volved in the management of different pathologies, knowing
their cost, and their social return are of great importance at a
time when the general budgets for healthcare are declining,
and when the timing of investment is essential.
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